Market Overview

Mindray Offers Statement on Masimo Suit, Says Will 'Vigorously Defend the Actions'

Related MR
Benzinga's Top Downgrades
Stocks Hitting 52-Week Lows
Related MASI
Masimo Reports Encouraging PVI Study Results - Analyst Blog
UPDATE: BMO Capital Markets Reiterates on Masimo Following Mixed 3Q13 Results

Mindray Medical International Limited (NYSE: MR), a leading developer, manufacturer and marketer of medical devices worldwide, today announced a statement on Masimo Corporation's (NASDAQ: MASI) lawsuit against Mindray.

On December 21, 2012, Masimo Corporation ("Masimo") brought an action in the United States District Court for the Central District of California against Mindray DS USA Inc. and Shenzhen Mindray Bio-Medical Electronics Co., Ltd. Masimo alleges that Mindray DS USA, Inc.'s U.S. Beneview pulse oximeters and sensors infringe its nine asserted patents relating to pulse oximeters and sensors, and that Shenzhen Mindray Bio-Medical Electronics Co., Ltd breached its Purchase and License Agreement dated November 13, 2002, as amended, by failing to use best efforts to promote adoption of Masimo's oximeter technology. In addition to monetary damages, Masimo is seeking injunctive relief preventing further sale of Beneview products incorporating Mindray oximetry boards in the United States.

Mindray intends to vigorously defend the actions.

Posted-In: News Legal

 

Most Popular

Related Articles (MASI + MR)

Around the Web, We're Loving...

Partner Network

Get Benzinga's News Delivered Free